3Fleisch H. Mechanisms of action of the bisphosphonates[J]. Medicina, 1997,57 Suppl 1:65-75. 被引量：1
4Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new member of the tumor factor receptor and ligand families [ J ]. Endoer Rev, 1999,20 ( 3 ) : 345 -357. 被引量：1
5Theolcyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/ RANK/RANKL:involvement in the orchestration of pathophysiological bone remodeling[ J ]. Cytokine Growth Factor Rev,2004,15 (6) :457-475. 被引量：1
6Zou W, Hakim I, Tschoep K,et al. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism[J]. J Cell Biochem,2001,83( 1 ) :70-83. 被引量：1
7Sabokbar A, Kudo O, Athanasou NA, et al. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis[ J ]. J Ortho Res,2003,21 ( 1 ) :73-80. 被引量：1
8Schlesinger PH, Blair HC, Teitelbaum SL, et al. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption[J]. J Biol Chem,1997,272(6) :18636-18643. 被引量：1
9Rogers MJ, Benford HL, Coxon JP, et al. Cellular and molecular mechanisms of action of bisphosphonates [ J ]. Cancer,2000,88 ( 12 Suppl) :2961-2978. 被引量：1
10David P, Nguyen H, Barbier A, et al. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H^+ -ATPase [J]. J Bone Miner Res, 1996,11 (10) : 1498-1507. 被引量：1
